Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women

References

• Palella FJ Jr, Baker RK, Moorman AC, et al. HIV outpatient study investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. doi: 10.1097/01.qai.0000233310.90484.16
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–29. doi: 10.1016/S0140-6736(03)13802-0
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–299. doi: 10.1016/S0140-6736(08)61113-7
   PubMed Web of Science ®Google Scholar
• United Nations Program on HIV/AIDS (UNAIDS): global HIV&AIDS statistics, in 2022: fact sheet. [cited 2024 Feb 3]. Available from: https://www.unaids.org/en/resources/fact-sheet
   Google Scholar
• World Health Organization. HIV/AIDS. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids
   Google Scholar
• Mother-to-child transmission of HIV. World Health Organization; [cited 2024 Feb 24]. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv
   Google Scholar
• Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015;61:1715–1725. doi: 10.1093/cid/civ578
   PubMed Web of Science ®Google Scholar
• Uthman OA, Nachega JB, Anderson J, et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV. 2017;4(1):e21–30. doi: 10.1016/S2352-3018(16)30195-3
   PubMed Web of Science ®Google Scholar
• Dionne B. Key principles of antiretroviral pharmacology. Infect Dis Clin North Am. 2019;33(3):787–805. doi: 10.1016/j.idc.2019.05.006
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Prevention of mother-to-child transmission of HIV: selection and use of nevirapine: technical notes. World Health Organization; 2001 [cited 2023 Nov 11]. Available from: https://iris.who.int/handle/10665/66808
   Google Scholar
• World Health Organization (WHO). Antiretroviral drugs for treating pregnant women and preventing HIV-infection in infants. World Health Organization; 2010 [cited 2023 Nov 11]. Available from: https://www.who.int/publications/i/item/9789241599818
   Google Scholar
• World Health Organization (WHO). Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2013 [cited 2023 Nov 11]. Available from: https://www.who.int/publications/i/item/9789241549684
   Google Scholar
• World Health Organization (WHO). Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. World Health Organization; 2021 [cited 2023 Nov 16]. Available from: who.int/publications-detail-redirect/9789240022232
   Google Scholar
• Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. [cited 2023 Nov 11]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/guidelines-perinatal.pdf
   Google Scholar
• European AIDS Clinical Society (EACS). guidelines, version 12.0. 2023 Oct [cited 2023 Nov 16]. Available from: https://www.eacsociety.org/media/guidelines-12.0.pdf
   Google Scholar
• Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):819–826. doi: 10.1053/beog.2001.0231
   PubMed Web of Science ®Google Scholar
• Eke AC, Gebreyohanes RD, Fernandes MFS, et al. Physiologic changes during pregnancy and impact on small-molecule drugs, biologic (monoclonal antibody) disposition, and response. J Clin Pharmacol. 2023;63(S1):S34–50. doi: 10.1002/jcph.2227
   PubMedGoogle Scholar
• Pinheiro EA, Stika CS. Drugs in pregnancy: pharmacologic and physiologic changes that affect clinical care. Semin Perinatol. 2020;44(3):151221. doi: 10.1016/j.semperi.2020.151221
   PubMed Web of Science ®Google Scholar
• Garrison KL, Sahin S, Benet LZ. Few drugs display flip-flop pharmacokinetics and these are primarily associated with classes 3 and 4 of the BDDCS. J Pharm Sci. 2015;104(9):3229–3235. doi: 10.1002/jps.24505
   PubMed Web of Science ®Google Scholar
• Melvin GC, Ellison SR, Monk CM, et al. Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. Res Commun Chem Pathol Pharmacol. 1990;70:193–204.
   PubMedGoogle Scholar
• Greene SA, Chen J, Prince HMA, et al. Population modeling highlights drug disposition differences between tenofovir alafenamide and tenofovir disoproxil fumarate in the blood and semen. Clin Pharmacol Ther. 2019;106(4):821–830. doi: 10.1002/cpt.1464
   PubMed Web of Science ®Google Scholar
• Bettonte S, Berton M, Stader F, et al. Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen. Br J Clin Pharmacol. 2023;89(12):3618–3628. doi: 10.1111/bcp.15867
   PubMed Web of Science ®Google Scholar
• Hytten F. Blood volume changes in normal pregnancy. Clin Haematol. 1985;14(3):601–612. doi: 10.1016/S0308-2261(21)00496-3
   PubMedGoogle Scholar
• Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013;41(2):256–262. doi: 10.1124/dmd.112.050245
   PubMed Web of Science ®Google Scholar
• Coppola P, Kerwash E, Cole S. Physiologically based pharmacokinetics model in pregnancy: a regulatory perspective on model evaluation. Front Pediatr. 2021;9:687978. doi: 10.3389/fped.2021.687978
   PubMed Web of Science ®Google Scholar
• Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633–639. doi: 10.1016/j.ajog.2004.08.030
   PubMed Web of Science ®Google Scholar
• Al-Enazy S, Ali S, Albekairib N, et al. Placental control of drug delivery. Adv Drug Deliv Rev. 2017;116:63–72. doi: 10.1016/j.addr.2016.08.002
   PubMed Web of Science ®Google Scholar
• Benaboud S, Tréluyer JM, Urien S, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012;56(2):776–782. doi: 10.1128/AAC.00370-11
   PubMed Web of Science ®Google Scholar
• Akanbi MO, Scarsi KK, Taiwo B, et al. Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. Expert Opin Pharmacother. 2012;13(1):65–79. doi: 10.1517/14656566.2012.642865
   PubMed Web of Science ®Google Scholar
• Fauchet F, Treluyer JM, Valade E, et al. Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour? Br J Clin Pharmacol. 2014;78(6):1387–1396. doi: 10.1111/bcp.12459
   PubMed Web of Science ®Google Scholar
• Andany N, Letchumanan M, Bondy L, et al. Amniocentesis in the HIV-infected pregnant woman: is there still cause for concern in the era of combination antiretroviral therapy? Can J Infect Dis Med Microbiol. 2013;24(3):e91–95. doi: 10.1155/2013/185192
   PubMed Web of Science ®Google Scholar
• Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006;20(4):553–560. doi: 10.1097/01.aids.0000210609.52836.d1
   PubMed Web of Science ®Google Scholar
• Schalkwijk S, Colbers A, Konopnicki D, et al. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women. AIDS. 2016;30(8):1239–1244. doi: 10.1097/QAD.0000000000001046
   PubMed Web of Science ®Google Scholar
• Fauchet F, Treluyer JM, Préta LH, et al. Population pharmacokinetics of abacavir in pregnant women. Antimicrob Agents Chemother. 2014;58(10):6287–6289. doi: 10.1128/AAC.03469-14
   PubMed Web of Science ®Google Scholar
• Ma JD, Lee KC, Kuo GM. HLA-B*5701 testing to predict abacavir hypersensitivity. PLOS Curr. 2010;2:RRN1203. doi: 10.1371/currents.RRN1203
   PubMedGoogle Scholar
• Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231. doi: 10.1177/2325958220919231
   Google Scholar
• Chittick GE, Zong J, Blum MR, et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother. 2006;50(4):1304–1310. doi: 10.1128/AAC.50.4.1304-1310.2006
   PubMed Web of Science ®Google Scholar
• Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008;74(1):92–100. doi: 10.1124/mol.108.045526
   PubMed Web of Science ®Google Scholar
• Birkus G, Wang R, Liu X, et al. Cathepsin a is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral phophonoamidate prodrugs GS-7340 and GC-9131. Antimicrob Agents Chemother. 2007;51(2):543–550. doi: 10.1128/AAC.00968-06
   PubMed Web of Science ®Google Scholar
• Gilead. TRUVADA (emtricitabine and tenofovir disoproxil fumarate) tablets for oral use drug label. 2004 [cited 2024 Feb 1]. Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/hiv/truvada/truvada_pi.pdf
   Google Scholar
• Osuala EC, Naidoo A, Dooley KE, et al. Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection. Expert Rev Clin Pharmacol. 2023;16(10):939–957. doi: 10.1080/17512433.2023.2251387
   PubMed Web of Science ®Google Scholar
• Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother. 1998;42(3):612–617. doi: 10.1128/AAC.42.3.612
   PubMed Web of Science ®Google Scholar
• Gasselin LD, Van Rompay KK, Vela JE, et al. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm. 2009;6(4):1145–1151. doi: 10.1021/mp900036s
   PubMedGoogle Scholar
• Ray A, Fordyce M, Hitchcock M. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of HIV. Antiviral Res. 2016;125:63–70. doi: 10.1016/j.antiviral.2015.11.009
   PubMed Web of Science ®Google Scholar
• Huliciak M, Lhotska I, Kocova-Vlckova H, et al. Effect of P-glycoprotein and cotreatment with sofosbuvir on the intestinal permeation of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate. Pharm Res. 2023;40(9):2109–2120. doi: 10.1007/s11095-023-03581-2
   PubMed Web of Science ®Google Scholar
• Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815. doi: 10.1056/NEJMoa1902824
   PubMed Web of Science ®Google Scholar
• Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502–511. doi: 10.1111/hiv.12252
   PubMed Web of Science ®Google Scholar
• Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLOS ONE. 2011;6(7):e22661. doi: 10.1371/journal.pone.0022661
   PubMed Web of Science ®Google Scholar
• Thimm MA, Livingston A, Ramroop R, et al. Pregnancy outcomes in pregnant women with HIV on tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF). J AIDS HIV Treat. 2022;4:6–13.
   PubMedGoogle Scholar
• Delahunty T, Bushman L, Robbins B, et al. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1907–1914. doi: 10.1016/j.jchromb.2009.05.029
   PubMed Web of Science ®Google Scholar
• Brooks KM, Pinilla M, Stek AM, et al. Pharmacokinetics of tenofovir alafenamide with boosted protease inhibitors in pregnant and postpartum women living with HIV: results from IMPAACT P1026s. J Acquir Immune Defic Syndr. 2022;90(3):343–350. doi: 10.1097/QAI.0000000000002944
   PubMed Web of Science ®Google Scholar
• Zhang H, Hindman T, Lin L, et al. A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV. AIDS. 2024;38(1):F1–9. doi: 10.1097/QAD.0000000000003783
   PubMed Web of Science ®Google Scholar
• Gilead Sciences. Emtriva package insert. [cited 2021 Feb 1]. Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/hiv/emtriva/emtriva_pi.pdf
   Google Scholar
• Stek AM, Best BM, Luo W, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012;13(4):226–235. doi: 10.1111/j.1468-1293.2011.00965.x
   PubMed Web of Science ®Google Scholar
• Latham H, Oriel N, Spitznagel M, et al. Impact of integrase strand transfer inhibitor use during pregnancy on viral suppression at delivery and infant outcomes: a statewide retrospective cohort study. J Acquir Immune Defic Syndr. 2022;89(4):448–453. doi: 10.1097/QAI.0000000000002882
   PubMed Web of Science ®Google Scholar
• Moreira FL, Paz TA, Melli PPDS, et al. Total, unbound, renal, and hepatic clearances of raltegravir and the formation and elimination clearances of raltegravir glucuronide in pregnant women. Clin Pharmacol. 2023;63(9):1053–1060. doi: 10.1002/jcph.2287
   Google Scholar
• Mulligan N, Best BM, Wang J, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32(6):729–737. doi: 10.1097/QAD.0000000000001755
   PubMed Web of Science ®Google Scholar
• Nguyen B, Foisy MM, Hughes CA. Pharmacokinetics and safety of the integrase inhibitors elvitegravir and dolutegravir in pregnant women with HIV. Ann Pharmacother. 2019;53(8):833–844. doi: 10.1177/1060028019830788
   PubMed Web of Science ®Google Scholar
• Blonk MI, Colbers AP, Hidalgo-Tenorio C, et al. Raltegravir in HIV-1–infected pregnant women: pharmacokinetics, safety, and efficacy. Clin Infect Dis. 2015;61(5):809–816. doi: 10.1093/cid/civ366 Watts DH, Stek A, Best BM, et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr, 2014;67:375-81.
   PubMed Web of Science ®Google Scholar
• Watts DH, Stek A, Best BM, et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014;67(4):375–381. doi: 10.1097/QAI.0000000000000318
   PubMed Web of Science ®Google Scholar
• van der Galiën R, Ter Heine R, Greupink R, et al. Pharmacokinetics of HIV-Integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps. Clin Pharmacokinet. 2019;58:309–323. doi: 10.1007/s40262-018-0684-z
   PubMed Web of Science ®Google Scholar
• Zheng Y, Hirt D, Delmas S, et al. Effect of pregnancy on unbound raltegravir concentrations in the ANRS 160 RalFe Trial. Antimicrob Agents Chemother. 2020;64(10):e00759–20. doi: 10.1128/AAC.00759-20
   PubMed Web of Science ®Google Scholar
• Momper J, Nikanjam M, Best B, et al. Brief report: dolutegravir plasma protein binding and unbound concentrations during pregnancy and postpartum. J Acquir Immune Defic Syndr. 2023;94(4):332–336. doi: 10.1097/QAI.0000000000003281
   PubMed Web of Science ®Google Scholar
• Bollen P, Freriksen J, Konopnicki D, et al. Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNant women network. The effect of pregnancy on the pharmacokinetics of total and unbound dolutegravir and its main metabolite in women living with human immunodeficiency virus. Clin Infect Dis. 2021;72:121–127. doi: 10.1093/cid/ciaa006
   PubMed Web of Science ®Google Scholar
• Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLOS Med. 2019;16(9):e1002895. doi: 10.1371/journal.pmed.1002895
   PubMed Web of Science ®Google Scholar
• Meyers K, Qian H, Wu Y, et al. Early initiation of ARV during pregnancy to move towards virtual elimination of mother-to-child-transmission of HIV-1 in Yunnan, China. PLOS ONE. 2015;10(9):e0138104. doi: 10.1371/journal.pone.0138104
   PubMed Web of Science ®Google Scholar
• Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021;397(10281):1276–1292. doi: 10.1016/S0140-6736(21)00314-7
   PubMed Web of Science ®Google Scholar
• van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–118. doi: 10.1016/S1473-3099(11)70290-0
   PubMed Web of Science ®Google Scholar
• Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353–361. doi: 10.1124/dmd.112.048918
   PubMed Web of Science ®Google Scholar
• German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323–329. doi: 10.1097/QAI.0b013e3181eb376b
   PubMed Web of Science ®Google Scholar
• Marzolini C, Decosterd L, Winterfeld U, et al. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. Br J Clin Pharmacol. 2017;83(12):2835–2838. doi: 10.1111/bcp.13310
   PubMed Web of Science ®Google Scholar
• Schalkwijk S, Colbers A, Konopnicki D, et al. First reported use of elvitegravir and cobicistat during pregnancy. AIDS. 2016;30(5):807–808. doi: 10.1097/QAD.0000000000000976
   PubMed Web of Science ®Google Scholar
• Patel P, Ford S, Baker M, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med. 2023;24(5):568–579. doi: 10.1111/hiv.13439
   PubMed Web of Science ®Google Scholar
• Delany-Moretlwe S, Hughes J, Guo X, et al. Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084. In: Presented at: 29th Conference on Retroviruses and Opportunistic Infections (CROI); Denver, Colorado, USA; 2022 Feb 12–16. Poster 00700.
   Google Scholar
• Crauwels H, Rice D, Neyens M, et al. Rilpivirine long-acting pharmacokinetic tail and pregnancy. In: E-poster presented at: 11th International Workshop on HIV & Women; 2021 Apr 26–28; Virtual Meeting Abstract 14.
   Google Scholar
• Efavirenz 600 mg film-coated tablets SmPC. [cited 2023 Nov 14]. Available from: https://www.medicines.org.uk/emc/product/13538/smpc#about-medicine
   Google Scholar
• Lartey M, Kenu E, Lassey A, et al. Pharmacokinetics of efavirenz 600 mg once daily during pregnancy and post partum in Ghanaian women living with HIV. Clin Ther. 2020;42(9):1818–1825. doi: 10.1016/j.clinthera.2020.07.008
   PubMed Web of Science ®Google Scholar
• Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012;59(3):245–252. doi: 10.1097/QAI.0b013e31823ff052
   PubMed Web of Science ®Google Scholar
• Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis. 2015;211(2):197–205. doi: 10.1093/infdis/jiu429
   PubMed Web of Science ®Google Scholar
• Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health. 2018;6(7):e804–10. doi: 10.1016/S2214-109X(18)30218-3
   PubMed Web of Science ®Google Scholar
• Smith C, Silveira L, Crotteau M, et al. Modern antiretroviral regimens in pregnant women: virologic outcomes and durability. AIDS. 2024;38(1):21–29. doi: 10.1097/QAD.0000000000003616
   PubMed Web of Science ®Google Scholar
• Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32(3):194–209. doi: 10.2165/00003088-199732030-00003
   PubMed Web of Science ®Google Scholar
• Eke AC, Mirochnick M. Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women. Expert Opin Drug Metab Toxicol. 2019;15(7):523–525. doi: 10.1080/17425255.2019.1628947
   PubMed Web of Science ®Google Scholar
• Boyd SD, Sampson MR, Viswanathan P, et al. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint. AIDS. 2019;33(6):1089–1093. doi: 10.1097/QAD.0000000000002163
   PubMed Web of Science ®Google Scholar
• Momper JD, Best B, Wang J, et al. Pharmacokinetics of darunavir boosted with cobicistat during pregnancy and postpartum. In: 2018; 10th IAS Conference on HIV Science (IAS 2018); 2021 Jul 18–21, Virtual Meeting, WEPEB118.
   Google Scholar
• Molto J, Curran A, Miranda C, et al. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. J Antimicrob Chemother. 2018;73(3):732–737. doi: 10.1093/jac/dkx459
   PubMed Web of Science ®Google Scholar
• Crowell CS, Williams PL, Yildirim C, et al. Pediatric HIV/AIDS cohort study. Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected. AIDS. 2020;34(9):1377–1387. doi: 10.1097/QAD.0000000000002550
   PubMed Web of Science ®Google Scholar
• Gacic N, Tulloch K, Money D, et al. Daily ritonavir-boosted darunavir for viral suppression in pregnancy (DRV-P). HIV Med. 2024;25(1):129–134. doi: 10.1111/hiv.13546
   PubMed Web of Science ®Google Scholar
• Colbers A, Molto J, Ivanovic J, et al. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. J Antimicrob Chemother. 2015;70(2):534–542. doi: 10.1093/jac/dku400
   PubMed Web of Science ®Google Scholar
• Zorrilla CD, Wright R, Osiyemi OO, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med. 2014;15:50–56. doi: 10.1111/hiv.12047
   PubMed Web of Science ®Google Scholar
• Lambert J, Jackson V, Else L, et al. Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc. 2014;17(4S3):19485. doi: 10.7448/IAS.17.4.19485
   PubMedGoogle Scholar
• Kreitchmann R, Best BM, Wang J, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr. 2013;63(1):59–66. doi: 10.1097/QAI.0b013e318289b4d2
   PubMed Web of Science ®Google Scholar
• Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19(9):825–835. doi: 10.1089/088922203769232629
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56(5):412–419. doi: 10.1097/QAI.0b013e31820fd093
   PubMed Web of Science ®Google Scholar
• Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48(6):2091–2096. doi: 10.1128/AAC.48.6.2091-2096.2004
   PubMed Web of Science ®Google Scholar
• Le MP, Mandelbrot L, Descamps D, et al. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women. Antivir Ther. 2015;20(5):507–513. doi: 10.3851/IMP2936
   PubMed Web of Science ®Google Scholar
• Perry M, Taylor G, Sabin C, et al. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates. HIV Med. 2016;17:28–35. doi: 10.1111/hiv.12277
   PubMed Web of Science ®Google Scholar
• Santini-Oliveira M, Estrela Rde C, Veloso VG, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother. 2014;58(5):2884–2893. doi: 10.1128/AAC.02599-13
   PubMed Web of Science ®Google Scholar
• Sha BE, Tierney C, Sun X, et al. Pharmacokinetic exposure and virologic response in HIV-1 infected pregnant women treated with lopinavir/ritonavir: aids clinical trials group protocol A5153s: a substudy to A5150. Jacobs J AIDS HIV. 2015;1:003.
   PubMedGoogle Scholar
• Sanford Guide Mobile App. [cited 2024 Feb 1]. Available from: https://www.sanfordguide.com/products/digital-subscriptions/mobile-apps/
   Google Scholar
• Lexi-Drugs. [cited 2024 Feb 1]. Available from: https://online.lexi.com
   Google Scholar
• Combivir 150 mg/300 mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/935/smpc
   Google Scholar
• Abacavir 300 mg film-coated tablets SmPC. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/10525/smpc
   Google Scholar
• Descovy 200 mg/10 mg film coated tablets SmPC. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/2107/smpc
   Google Scholar
• Delstrigo 100 mg/300 mg/245 mg film-coated tablets SmPC. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/9694/smpc
   Google Scholar
• Genvoya 150mg/150mg/200mg/10mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/5063/smpc
   Google Scholar
• Efavirenz 600 mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/13538/smpc
   Google Scholar
• Edurant 25 mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/4968/smpc
   Google Scholar
• Darunavir 600 mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/13536/smpc
   Google Scholar
• Atazanavir 200 mg capsules, hard. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/10778/smpc
   Google Scholar
• Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Investig Drugs. 2002;11(9):1295–1301. doi: 10.1517/13543784.11.9.1295
   PubMed Web of Science ®Google Scholar
• Lopinavir. [cited 2024 Feb 3]. Available from: https://go.drugbank.com/drugs/DB01601
   Google Scholar
• Kaletra (80 mg + 20 mg)/ml oral solution. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/1315/smpc
   Google Scholar
• Crommentuyn KM, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005;60(4):378–389. doi: 10.1111/j.1365-2125.2005.02455.x
   PubMed Web of Science ®Google Scholar
• Isentress 400 mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/6171/Smpc
   Google Scholar
• Temesgen Z, Siraj DS. Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manag. 2008;4:493–500. doi: 10.2147/TCRM.S2268
   PubMedGoogle Scholar
• Flexner CW. Antiretroviral agents and treatment of HIV infection. In: Brunton L, Knollmann B, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 14 ed. New York (NY): McGraw Hill; 2023:13e.
   Google Scholar
• Dovato 50 mg/300 mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/10446/smpc
   Google Scholar
• Biktarvy 50 mg/200 mg/25 mg film-coated tablets. [cited 2024 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/9313/smpc
   Google Scholar
• Chaphekar N, Dodeja P, Shaik IH, et al. Maternal-fetal pharmacology of drugs: a review of current status of the application of physiologically based pharmacokinetic models. Front Pediatr. 2021;9:733823. doi: 10.3389/fped.2021.733823
   PubMed Web of Science ®Google Scholar
• Adiwidjaja J, Boddy AV, McLachlan AJ. A strategy to refine the phenotyping approach and tts implementation to predict drug clearance: a physiologically based pharmacokinetic simulation study. CPT Pharmacometrics Syst Pharmacol. 2018;7:798–808. doi: 10.1002/psp4.12355
   PubMedGoogle Scholar
• Eke AC, Olagunju A, Best BM, et al. Innovative approaches for pharmacology studies in pregnant and lactating women: a viewpoint and lessons from HIV. Clin Pharmacokinet. 2020;59(10):1185–1194. doi: 10.1007/s40262-020-00915-w
   PubMed Web of Science ®Google Scholar
• Eke AC, Shoji K, Best BM, et al. Population pharmacokinetics of tenofovir in pregnant and postpartum women using tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2021;65(3):e02168–20. doi: 10.1128/AAC.02168-20
   PubMed Web of Science ®Google Scholar
• Hu K, Fu M, Huang X, et al. Editorial: model-informed drug development and precision dosing in clinical pharmacology practice. Front Pharmacol. 2023;14:1224980. doi: 10.3389/fphar.2023.1224980
   PubMed Web of Science ®Google Scholar
• Pérez-Blanco JS, Lanao JM. Model-informed precision dosing (MIPD). Pharmaceutics. 2022;14(12):2731. doi: 10.3390/pharmaceutics14122731
   PubMed Web of Science ®Google Scholar
• Touw DJ. Saliva for Model informed precision dosing. Expert Rev Clin Pharmacol. 2023;16(8):687–689. doi: 10.1080/17512433.2023.2223969
   PubMed Web of Science ®Google Scholar
• Yamada E, Takagi R, Moro H, et al. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma. PLOS ONE. 2021;16(2):e0246994. doi: 10.1371/journal.pone.0246994
   PubMed Web of Science ®Google Scholar
• Coppola P, Butler A, Cole S, et al. Total and free blood and plasma concentration changes in pregnancy for medicines highly bound to plasma proteins: application of physiologically based pharmacokinetic modelling to understand the impact on efficacy. Pharmaceutics. 2023;15(10):2455. doi: 10.3390/pharmaceutics15102455
   PubMed Web of Science ®Google Scholar
• Balhara A, Kumar AR, Unadkat JD. Predicting human fetal drug exposure through maternal-fetal PBPK modeling and in vitro or ex vivo studies. J Clin Pharmacol. 2022;62(S1):S94–114. doi: 10.1002/jcph.2117
   PubMedGoogle Scholar
• Anoshchenko O, Milad MA, Unadkat JD. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome. CPT Pharmacometrics Syst Pharmacol. 2021;10(9):1057–1070. doi: 10.1002/psp4.12674
   PubMedGoogle Scholar
• Zhang Z, Imperial MZ, Patilea-Vrana GI, et al. Development of a novel maternal-fetal physiologically based pharmacokinetic Model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses. Drug Metab Dispos. 2017;45(8):920–938. doi: 10.1124/dmd.117.075192
   PubMed Web of Science ®Google Scholar
• Coppola P, Kerwash E, Cole S. The use of pregnancy physiologically based pharmacokinetic modeling for renally cleared drugs. J Clin Pharmacol. 2022;62(S1):S129–39. doi: 10.1002/jcph.2110
   PubMedGoogle Scholar
• Colbers A, Greupink R, Litjens C, et al. Physiologically based modelling of darunavir/ritonavir pharmacokinetics during pregnancy. Clin Pharmacokinet. 2016;55(3):381–396. doi: 10.1007/s40262-015-0325-8
   PubMed Web of Science ®Google Scholar
• Taskar KS, Harada I, Alluri RV. Physiologically-based pharmacokinetic (PBPK) modelling of transporter mediated drug absorption, clearance and drug-drug interactions. Curr Drug Metab. 2021;22(7):523–531. doi: 10.2174/1389200221999210101233340
   PubMed Web of Science ®Google Scholar
• Taskar KS, Pilla Reddy V, Burt H, et al. Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: Current capabilities, case studies, future opportunities, and recommendations. Clin Pharmacol Ther. 2020;107(5):1082–1115. doi: 10.1002/cpt.1693
   PubMed Web of Science ®Google Scholar
• Physiologically based pharmacokinetic analyses -format and content. [cited 2024 Mar 7]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry
   Google Scholar
• Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. [cited 2024 Mar 7]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-and-simulation_en.pdf
   Google Scholar
• Drwal E, Rak A, Gregoraszczuk E. Co-culture of JEG-3, BeWo and syncBewo cell lines with adrenal H295R cell line: an alternative model for examining endocrine and metabolic properties of the fetoplacental unit. Cytotechnology. 2018;70(1):285–297. doi: 10.1007/s10616-017-0142-z
   PubMed Web of Science ®Google Scholar
• Eke AC, Olagunju A, Momper J, et al. participants of the WHO-IMPAACT workshop on “approaches to optimize and accelerate pharmacokinetic studies in pregnant and lactating women”. Optimizing pharmacology studies in pregnant and lactating women using lessons from HIV: a consensus statement. Clin Pharmacol Ther. 2021;110(1):36–48. doi: 10.1002/cpt.2048
   PubMed Web of Science ®Google Scholar
• Neumanova Z, Cerveny L, Ceckova M, et al. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS. 2014;28(1):9–17. doi: 10.1097/QAD.0000000000000112
   PubMed Web of Science ®Google Scholar
• Vinot C, Gavard L, Tréluyer JM, et al. Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression. Antimicrob Agents Chemother. 2013;57:1415–1420. doi: 10.1128/AAC.01821-12
   PubMed Web of Science ®Google Scholar
• Ikumi NM, Anumba D, Matjila M. Pharmacokinetics and placental transfer of dolutegravir in pregnancy. J Antimicrob Chemother. 2022;77(2):283–289. doi: 10.1093/jac/dkab365
   PubMed Web of Science ®Google Scholar
• Eke AC, Mirochnick M, Lockman S, et al. Antiretroviral therapy and adverse pregnancy outcomes in people living with HIV. N Engl J Med. 2023;388(4):344–356. doi: 10.1056/NEJMra2212877
   PubMed Web of Science ®Google Scholar
• Alvarez-Requejo A, Carvajal A, Bégaud B, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483–488. doi: 10.1007/s002280050498
   PubMed Web of Science ®Google Scholar
• Wall KM, Haddad LB, Mehta CC, et al. Miscarriage among women in the United States Women’s interagency HIV study, 1994–2017. Am J Obstet Gynecol. 2019;221(4):.e347.1–.e347.13. doi: 10.1016/j.ajog.2019.05.034
   Web of Science ®Google Scholar
• Hoffman RM, Brummel SS, Britto P, et al. Adverse pregnancy outcomes among women who conceive on antiretroviral therapy. Clin Infect Dis. 2019;68(2):273–279. doi: 10.1093/cid/ciy471
   PubMed Web of Science ®Google Scholar
• Theron G, Brummel S, Fairlie L, et al. Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy. Clin Infect Dis. 2021;73(2):e312–20. doi: 10.1093/cid/ciaa805
   PubMed Web of Science ®Google Scholar
• Stringer EM, Kendall MA, Lockman S, et al. Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy. PLOS ONE. 2018;13(7):e0199555. doi: 10.1371/journal.pone.0199555
   PubMed Web of Science ®Google Scholar
• Da Silva F T, Gonik B, M M, et al. Brighton Collaboration Stillbirth Working Group. Stillbirth: case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2016;34(49):6057–6068. doi: 10.1016/j.vaccine.2016.03.044
   PubMed Web of Science ®Google Scholar
• Zash R, Jacobson DL, Diseko M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr. 2017;171(10):e172222. doi: 10.1001/jamapediatrics.2017.2222
   PubMed Web of Science ®Google Scholar
• Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506–514. doi: 10.1093/infdis/jir307
   PubMed Web of Science ®Google Scholar
• Quinn MK, Williams PL, Muhihi A, et al. Timing of antiretroviral therapy: initiation and birth outcomes among pregnant women with human immunodeficiency virus in Tanzania. J Infect Dis. 2022;226(4):687–695. doi: 10.1093/infdis/jiac224
   PubMed Web of Science ®Google Scholar
• Xiao PL, Zhou YB, Chen Y, et al. Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies. Bmc Pregnancy Childbirth. 2015;15(1):246. doi: 10.1186/s12884-015-0684-z
   PubMed Web of Science ®Google Scholar
• Cowdell I, Beck K, Portwood C, et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: a systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368. doi: 10.1016/j.eclinm.2022.101368
   PubMedGoogle Scholar
• Pereira GFM, Kim A, Jalil EM, et al. National Cohort Study of Dolutegravir and pregnancy outcomes in Brazil. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8(1):e33–41. doi: 10.1016/S2352-3018(20)30268-X
   PubMed Web of Science ®Google Scholar
• Dugdale CM, Ciaranello AL, Bekker LG, et al. Risks and benefits of dolutegravir- and efavirenz-based strategies for South African women with HIV of child-bearing potential: a modeling study. Ann Intern Med. 2019;170(9):614–625. doi: 10.7326/M18-3358
   PubMed Web of Science ®Google Scholar
• Williams PL, Yildirim C, Chadwick EG, et al. Surveillance monitoring for ART toxicities (SMARTT) study of the pediatric HIV/AIDS cohort study. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study. Lancet HIV. 2020;7(1):e49–58. doi: 10.1016/S2352-3018(19)30340-6
   PubMed Web of Science ®Google Scholar
• Sirois PA, Huo Y, Williams PL, et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J. 2013;32(6):648–655. doi: 10.1097/INF.0b013e318284129a
   PubMed Web of Science ®Google Scholar
• Kintu K, Malaba TR, Nakibuka J, et al. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV. 2020;7(5):e332–9. doi: 10.1016/S2352-3018(20)30050-3
   PubMed Web of Science ®Google Scholar
• Joseph NT, Satten GA, Williams RE, et al. The effect of antiretroviral therapy for the treatment of human immunodeficiency virus (HIV)-1 in pregnancy on gestational weight gain. Clin Infect Dis. 2022;75(4):665–672. doi: 10.1093/cid/ciab994
   PubMed Web of Science ®Google Scholar
• Coutinho CM, Warshaw MG, Duarte G, et al. Effects of initiating raltegravir-based versus efavirenz-based antiretroviral regimens during pregnancy on weight changes and perinatal outcomes: NICHD P1081. J Acquir Immune Defic Syndr. 2022;91(4):403–409. doi: 10.1097/QAI.0000000000003081
   PubMed Web of Science ®Google Scholar
• Soepnel LM, Norris SA, Schrier VJ, et al. The association between HIV, antiretroviral therapy, and gestational diabetes mellitus. AIDS. 2017;31:113–125. doi: 10.1097/QAD.0000000000001277
   PubMed Web of Science ®Google Scholar
• Premkumar A, Dude AM, Haddad LB, et al. Combined antiretroviral therapy for HIV and the risk of hypertensive disorders of pregnancy: a systematic review. Pregnancy Hypertens. 2019;17:178–190. doi: 10.1016/j.preghy.2019.05.015
   PubMed Web of Science ®Google Scholar
• Fafin C, Pugliese P, Durant J, et al. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2. Nephron Clin Pract. 2012;120(4):c205–14. doi: 10.1159/000342377
   PubMedGoogle Scholar
• Floridia M, Masuelli G, Ravizza M, et al. Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study. J Antimicrob Chemother. 2018;73(4):1025–1030. doi: 10.1093/jac/dkx478
   PubMed Web of Science ®Google Scholar
• Sibiude J, Warszawski J, Tubiana R, et al. Liver enzyme elevation in pregnant women receiving antiretroviral therapy in the ANRS-French perinatal cohort. J Acquir Immune Defic Syndr. 2019;81(1):83–94. doi: 10.1097/QAI.0000000000001963
   PubMed Web of Science ®Google Scholar
• Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161:1–10. doi:10.7326/M14-0293 Erratum in: Ann Intern Med. 2014;161:308.
   PubMed Web of Science ®Google Scholar
• van der Wekken-Pas L, Nassiwa S, Malaba T, et al. Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy. AIDS. 2024;38(7):975–981. doi: 10.1097/QAD.0000000000003852
   PubMed Web of Science ®Google Scholar
• CIOMS international ethical guidelines for health-related research involving humans. [cited 2024 Feb 3]. Available from: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf
   Google Scholar